Allergan Inc: (NYSE: AGN)

$97.73

-0.81 (-0.82%)

Volume 2,798,059

May 22 04:01 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		97.46 - 99.33
	
		52wk Low - High
		81.28 - 116.45
	
		Previous Close
		98.54
	
		Avg. Volume
		3,066,183
	
		Industry
		LARGE CAP PHARMA
	
		Market Cap
		29.33 B
	
		Div - Yield
		0.20 - 0.20
	
		Beta
		0.84
	
		PE (Forward)
		20.73
	
		Current Year Est.
		4.75
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		176 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/2/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            20.73
                        
                            PEG Ratio
                            1.55
                        
                            Current Year Est.
                            4.75
                        
                            Current Quarter Estimate
                            1.20
                        
                            Most Accurate Estimate
                            1.20
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            4.26
                        
                            Expected Earnings Growth
                            13.38%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Allergan, Inc. is a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets. Its worldwide consolidated revenues are principally generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and skin care, neurotoxins, intraocular lenses and other ophthalmic surgical products, and contact lens care products.   
Full AGN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
AGN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.20	1.21	4.75	5.48
Number of Estimates	15	15	19	18
Low Estimate	1.18	1.18	4.71	5.28
High Estimate	1.25	1.26	4.88	NA
Year Ago EPS	1.07	1.06	4.14	4.75
EPS Growth	12.09%	14.53%	14.80%	15.30%

More AGN Estimates

Average Earnings Estimates for AGN

EPS Growth for AGN

Industry Analysis

Name	Symbol	Previous Close
ALLERGAN INC	AGN	98.54
ABBOTT LABS	ABT	37.72
ABBVIE INC	ABBV	46.54
ASTRAZENECA PLC	AZN	51.71
BAYER A G -ADR	BAYRY	109.36
BRISTOL-MYERS	BMY	44.06
GLAXOSMITHKLINE	GSK	52.65
JOHNSON & JOHNS	JNJ	88.59
LILLY ELI & CO	LLY	55.14
MERCK & CO INC	MRK	47.33

Sector:Medical>> Industry:LARGE CAP PHARMA

COMPARE TICKER vs. Its Peers

Zacks Commentary

Positive Opinion on Allergan Candidate

May 06, 2013

Allergan Beats on Earnings

May 01, 2013

A Look at LLY's Early Stage Oncology Pipeline

Apr 12, 2013

Roche Reports 1Q Sales

Apr 12, 2013

SNY's Vaxigrip Filing Accepted in EU

Apr 11, 2013

Roche's New Test for Thyroid Cancer

Apr 11, 2013

SNY's Aubagio Gets Argentinean Nod

Apr 10, 2013

The Zacks Analyst Blog Highlights: Safeway, Valeant Pharmaceuticals, Obagi Medical Products, Allergan and Avanir Pharmaceuticals

Apr 10, 2013

More AGN Zacks Commentary

Financials

EPS TTM	4.26
Sales	5,806
Net Income	882
Price/Earnings	23.13
Price/Book	5.47
Price/Cash Flow	19.90
Price/Sales	4.99

More AGN Financials

News

Research and Markets Adds Report: Allergan Partnering 2005-2013 - Close-Up Media

May 23, 2013

Allergan (AGN) Showing Bearish Technicals But Could Break Through $100.47 Resistance - Freshbrewedmedia

May 22, 2013

Allergan, Mentor and Galderma Lead the Accelerating European Market for Cosmetic Surgery, Facial Aesthetics and Medical Lasers Reports iData Research Inc. - Globenewswire

May 21, 2013

Allergan, Mentor and Galderma Lead the Accelerating European Market for Cosmetic Surgery, Facial Aesthetics and Medical Lasers Reports iData Research Inc. - Prweb

May 21, 2013

Botox - Is the World's Most Popular Cosmetic Procedure Safe? - Prweb

May 21, 2013

Shares of Allergan Under Pressure, Down 1.5% - Financial News Network Online - Market Movers

May 20, 2013

Allergan Earnings Hindsight: Up 0.7% in Last 17 Days (AGN) - Financial News Network Online - Earnings Lookback

May 18, 2013

Allergan Partnering 2005-2013 Provides an Orientation of Bigpharma's Dealmaking and Business Activities - M2

May 17, 2013

See All News Stories on AGN

Broker Recommendations

Current ABR	1.75
ABR (Last Week)	1.75
# of recs in ABR	24
Average Target Price	114.03
Industry Rank by ABR	176 out of 265
Rank in Industry	1 out of 15

More AGN Broker Recommendations

Day Low - High	97.46 - 99.33
52wk Low - High	81.28 - 116.45
Previous Close	98.54
Avg. Volume	3,066,183
Industry	LARGE CAP PHARMA
Market Cap	29.33 B
Div - Yield	0.20 - 0.20
Beta	0.84
PE (Forward)	20.73
Current Year Est.	4.75
Quarterly Earnings ESP	0.00%

PE (Forward)	20.73
PEG Ratio	1.55
Current Year Est.	4.75
Current Quarter Estimate	1.20
Most Accurate Estimate	1.20
Earnings ESP	0.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	4.26
Expected Earnings Growth	13.38%

Username: Password:

Remember me [?]

Allergan Inc: (NYSE: AGN)

$97.73

-0.81 (-0.82%)

Volume 2,798,059

May 22 04:01 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:LARGE CAP PHARMA

Zacks Commentary

Financials

News

Broker Recommendations